Agios Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de Agios Pharmaceuticals es Brian Goff , nombrado en Aug 2022, tiene una permanencia de 2.25 años. compensación anual total es $3.42M, compuesta por 23.4% salario y 76.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.14% de las acciones de la empresa, por valor de $4.37M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 7.6 años, respectivamente.
Información clave
Brian Goff
Chief Executive Officer (CEO)
US$3.4m
Compensación total
| Porcentaje del salario del CEO | 23.4% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 7.6yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Compensación vs. Mercado: La compensación total de Brian($USD3.42M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de Brian ha sido consistente con los resultados de la empresa en el último año.
CEO
Brian Goff (55 yo)
2.3yrs
Permanencia
US$3,416,453
Compensación
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. from June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.4m | |
| Chief Financial Officer | 2.2yrs | US$1.21m | 0.035% $ 1.1m | |
| Corporate Secretary & Chief Legal Officer | 2.8yrs | US$1.93m | 0.028% $ 869.8k | |
| Chief Medical Officer and Head of Research & Development | 3.2yrs | US$2.87m | 0.077% $ 2.4m | |
| Chief Commercial Officer | 1.8yrs | US$3.73m | 0.023% $ 733.3k | |
| Founder | no data | US$333.51k | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| VP, Controller & Principal Accounting Officer | 3.3yrs | sin datos | 0.0027% $ 84.4k | |
| Chief Technical Operations Officer | 7.4yrs | sin datos | sin datos | |
| Vice President of Investor Relations & Corporate Communications | no data | sin datos | sin datos |
2.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AGIO se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.42m | 0.14% $ 4.4m | |
| Chair of the Board of Directors | 6.9yrs | US$447.25k | 0.25% $ 7.8m | |
| Independent Director | 1.4yrs | US$663.68k | 0.0035% $ 109.3k | |
| Member of Scientific Advisory Board | 8.3yrs | US$302.85k | sin datos | |
| Member of Scientific Advisory Board | 15.8yrs | sin datos | sin datos | |
| Lead Independent Director | 9.9yrs | US$440.95k | 0.013% $ 418.3k | |
| Independent Director | 15.3yrs | US$417.25k | 0.83% $ 26.4m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 16yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 3.8yrs | US$3.21m | sin datos | |
| Independent Director | 2.3yrs | US$419.91k | 0.014% $ 442.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
7.6yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de AGIO se considera experimentada (7.6 años de antigüedad promedio).